CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Therapeutic Solutions International Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Therapeutic Solutions International Inc
701 Wild Rose Lane
Phone: (760) 295-7208p:760 295-7208 ELK CITY, ID  83525  United States Ticker: TSOITSOI
Business Summary
Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury, and for daily health. The Company's flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The Company also sells certain nutraceuticals. The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
3843 Dental equipment and supplies
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Timothy G.Dixon 64 12/1/2011 3/31/2011
Chief Scientific Officer FengLin 52
Vice President - Business Development FamelaRamos 46
Chief Medical Officer JamesVeltmeyer 57 6/18/2018 6/18/2018
Director Thomas E.Ichim 47 1/22/2016 1/22/2016

Business Names
Business Name
30, 60, and 90.
ALS Biologics, Inc.
Cord Derived Regenerative and Immune Modulatory Stem Cell Populations.
7 additional Business Names available in full report.

General Information
Number of Employees: 3 (As of 12/31/2022)
Outstanding Shares: 4,230,116,869 (As of 4/17/2024)
Shareholders: 208
Stock Exchange: OTC
Federal Tax Id: 331176182


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024